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In 2014, specific recommendations for complement nomenclature were presented by
the complement field. There remained some unresolved designations and new areas
of ambiguity, and here we propose solutions to resolve these remaining issues. To
enable rapid understanding of the intricate complement system and facilitate therapeutic
development and application, a uniform nomenclature for cleavage fragments, pattern
recognition molecules (PRMs) and enzymes of the lectin pathway and regulatory proteins
of the complement system are proposed, and a standardization of language to designate
different activation states of complement components is recommended.
Keywords: complement, nomenclature, C1, C1q, C2, lectin pathway, collectins, clusterin
INTRODUCTION
The complement system is composed of more than 50 different molecules and cleavage products
including but not limited to pattern recognition molecules (PRMs), proenzymes, proteases,
anaphylatoxins, opsonins, receptors, regulators, and multi-molecular complexes that are critical
to host defense and maintenance of normal tissue homeostasis (1). While traditional functions
of the complement system in host defense and clearance of cellular debris have long been
appreciated, continued advancement in the field has revealed additional roles for complement from
embryogenesis to aging, in both healthy and disease states (Figure 1A) (2–4). In addition, successful
development of the anti-human C5monoclonal antibody, eculizumab, for treatment in paroxysmal
nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis
has renewed interest in clinical applications for complement within the medical field for treatment
as well as diagnosis. Consequently, researchers in multiple fields even beyond immunology are
investigating various components and pathways of the complement system.
To facilitate advancement and communication in both basic research and clinical application
in the field, it is important to standardize complement nomenclature. Following a joint effort of
the International Complement Society (ICS) and the European Complement Network (ECN) to
simplify and clarify complement nomenclature, a list of recommended names for complement
pathways, proteins, protein complexes, and receptors was established in 2014 (5), and the
recommendations from that effort are shown in Table 1. This update to complement nomenclature
was the first since 1981. While comprehensive, consensus was not reached on several issues. Here
we propose recommendations and updates for nomenclature regarding four of these unresolved
issues: (1) the cleavage products of C2, (2) C1 complexes- activated molecules, native molecules, or
proenzymes, (3) lectin pathway recognition proteins and enzymes and (4) Clusterin.
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FIGURE 1 | (A) Complement activities control key cellular processes and contribute to a broad range of disease states. It is now broadly acknowledged that
complement functions well beyond mere protection against invading pathogens but participates actively in the control of key physiological processes. Therefore,
complement is key to normal cell and tissue homeostasis and aberrant complement activation (either too little or too much) can hence cause or contribute to a broad
range of disease settings including recurrent infections and cancer (too little) or auto-immunity and fibrosis (too much). (B) Schematic representation of C3 family
members, FB, and C2. While convention holds that smaller fragments (yellow for C3, C4, C5, and FB) retain earlier letters than larger fragments (Blue for C3, C4, C5,
and FB), C2 breaks with convention (C2 current). To facilitate communication in the field and better standardize complement nomenclature, we recommend adopting
standard convention for C2 (C2 recommended). (H) Indicates cleavage site for liberation of smaller fragment. (C) C1 is a complex macromolecular structure consisting
of C1q, C1r, and C1s. C1 circulates in blood as an “unactivated” complex of the recognition protein, C1q (yellow), and two molecules each of the proenzymes C1r and
Cls (blue and green ellipses). Conformational changes induced by binding to an activator result in activated C1 due to the conversion of C1r and C1s to active serine
proteases (blue and green triangles). C1s proceeds to cleave C4 and C2 which results ultimately in the formation of the classical pathway C3 convertase, C4b2b.
Generation of opsonic C3b and iC3b, and subsequently C5a and C5b-9 (not shown) mediate the possible complement effector functions that follow. Four C1-INH
molecules per C1 (only representative complexes are shown) are required to inactivate the serine proteases, C1r and C1s, and results in their dissociation from C1q,
thereby regulating the amount of C4b2b generated. In the lower row, C1q can be synthesized in tissue to “silently” eliminate apoptotic cells and cellular debris.
THE CLEAVAGE PRODUCTS OF C2
In general, complement cleavage fragments are designated with
letters according to their relative size with “a” fragments smaller
than “b” fragments. Figure 1B is a schematic depicting members
of the C3 family, as well as Factor B (FB) of the alternative
pathway, for which the nomenclature follows this convention. In
all of these cases (C3, C4, C5, FB), the larger fragment remains cell
associated, and the smaller fragment diffuses from the original
site of cleavage. Moreover, C3 family members (C3, C4, and C5)
share similar structures, and the smaller cleavage products (C3a,
C4a, and C5a) of these molecules all engage receptors on cells to
trigger signaling pathways and activation processes. Convention
is followed for FB, where the smaller, diffusible fragment, Ba, is
liberated from the larger fragment, Bb, which remains associated
with activator bound C3b. The serine protease domain of FB is
within the Bb fragment.
Current nomenclature in popular use for C2 breaks
convention in that the smaller fragment is often referred to
as “C2b” and the larger fragment “C2a” (Figure 1B, current
nomenclature). Originally, and prior to detailed knowledge of
the activation mechanisms involved, the activated C2 molecule
was designated as C’2a (6) and refers to the generated ability
of C2 to enable/activate the cascade to continue through
C3 and ultimately generate a hemolytic activity. However, a
challenge to the fragment designation was debated as early as
the late 70’s, when the protein structure and function clearly
showed the lack of conformity with the nomenclature of the
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other complement activation fragments. Factor B and C2 are
homologous proteins [39% sequence similarity (7)], and as
such Ba is similar in structure and function to the smaller C2
fragment, and Bb is similar in structure and function to the
larger C2 cleavage product. Previous attempts to amend this
lack of consistency in the fragment designation [for example, as
adopted in Fundamentals of Immunology (8) and editions 1–6 of
Janeway’s Immunobiology and other texts] were not sustained.
We propose that it is time to align the C2 nomenclature
with the other complement proteins (Figure 1B, recommended
nomenclature). This becomes exceptionally apparent to the
student (or instructor) of complement when given the challenge
of understanding and communicating a robust system of
pathways, receptors and regulators. C2 is clearly the outlier
when working through the pathways of complement activation,
and it adds ambiguity to a system of pathways that is already
challenging to effectively communicate. The argument against
adopting the conventional nomenclature for C2 is that it is
established in the literature now in a non-conventional format.
The counter argument is that it is estimated that our scientific
output is doubling approximately every 9 years (9). With the
recent resurgence of interest and therapeutic development in
the complement field, it will benefit the next generation of
complement biologists to learn and work within a system that is
“as simple, as clear and as unambiguous as possible” (5).
C1 COMPLEXES (UNACTIVATED/
ACTIVATED/INACTIVATED)
There no longer is a specific designation for the classical
complement pathway (CP) proenzymes C1r andC1s or the native
zymogen C1 complex vs. activated C1r, C1s, or C1. However,
to avoid confusion and therefore facilitate progress toward
identification of effective therapeutic targets and therapeutic
development, it is critical to accurately describe these various
states of the complement components. C1 is a Ca++ dependent
macromolecular complex comprised of C1q (itself a hexamer
of trimers of 3 distinct protein chains C1qA, C1qB, and
C1qC), and two molecules each of the proenzymes C1r and
C1s (Figure 1C). In blood (or serum), most of the C1q
(90%) is found in complex with the proenzymes C1r2C1s2
(10), and this is “unactivated C1” (or native zymogen C1).
That is, under physiologic conditions (vs. a contrived in vitro
situation), C1q is already complexed to C1r2C1s2 when it
binds to an activator. C1q does not normally bind an activator
and then “recruit C1r and C1s,” as has been misstated in
recent literature.
When C1q within this C1 binds to “activators,” the C1q
molecule is constrained in a conformation that enables C1r and
C1s to be cleaved to active enzymes (C1r is autocatalytically
cleaved and cleaves C1s). The activated C1s (which now converts
the C1 complex to “activated C1”) propagates CP activity
by cleaving the next proteins in the cascade as illustrated
(Figure 1C). C1 Inhibitor (C1-INH) is an important regulator
of this enzymatic activity that rapidly binds covalently in the
TABLE 1 | (Top) Complement nomenclature as per International Complement
Society (ICS) Complement Nomenclature Committee, and ICS and
European Complement Network (ECN) boards recommendation from 2014
[reproduced with permission (5)].
Recommended 2014 Recommended 2014
Name Comments Name Comments
Pathways Proteins (cont.)
CP Classical pathway MBL Mannose-binding
lectin
AP Alternative pathway Ficolin-1 Ficolin M
LP Lectin pathway Ficolin-2 Ficolin L
TP Terminal pathway
(C5, C6, C7, C8, and
C9)
Ficolin-3 Ficolin H
Proteins MASP-1 MBL-associated
serine protease 1
C1 Complex of C1q,
2C1r, 2C1s
MASP-2 MBL-associated
serine protease 2
C1q MASP-3 MBL-associated
serine protease 3
C1r FHL-1 Factor H-like protein
1
C1s FHR-1 Factor H-related
protein 1
C1-INH C1 Esterase inhibitor FHR-2 Factor H-related
protein 2
C2 FHR-3 Factor H-related
protein 3
C3 FHR-4 Factor H-related
protein 4
C3(H2O) Thioester-hydrolyzed
form of C3
FHR-5 Factor H-related
protein 5
C3a Anaphylatoxin from
C3
CD59 Protectin,
Homologous
restriction factor
C3b Protein complexes
iC3b Inactivated C3b C5b6 Terminal pathway
complex of C5b + C6
C3dg C5b-7 Terminal pathway
complex of C5b6 +
C7
C3d C5b-8 Terminal pathway
complex of C5b-7 +
C8
C4 C5b-9 Terminal pathway
complete complex
C4a sC5b-9 Soluble C5b-9 with
Vn bound
C4a-desArg C4a without
C-terminal arginine
C3bBb AP C3 convertase
C4b C3bBbP AP C3 convertase
with properdin
C4d C3bBbC3b AP C3/C5 convertase
C4BP C4b binding protein C4BP-Protein S C4BP bound to
protein S
(Continued)
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TABLE 1 | Continued
Recommended 2014 Recommended 2014
Name Comments Name Comments
C5 Receptors
C5a Anaphylatoxin from
C5
CR1 CD35, C3b/C4b
receptor
C5a-desArg C5a without
C-terminal arginine
CR2 CD21, C3d receptor
C5b CR3 CD11b/CD18
complex
C6 CR4 CD11c/CD18
complex
C7 C3aR Requesting CD
number
C8 C5aR1 C5aR, CD88
C9 C5aR2 C5L2, requesting CD
number
Vn Vitronectin, S protein,
S40
CRIg Complement
receptor of the Ig
family
FB Factor B C1qR
FD Factor D gC1qR Recognizes globular
domains
FH Factor H cC1qR Recognizes collagen
domain, calreticulin
FI Factor I LHR Long homologous
repeat (CR1)
UPDATED COMPLEMENT NOMENCLATURE 2019
Proteins Lectin pathway
C2a Small C2 cleavage
fragment
CL-10 Collectin-10
C2b Large C2 cleavage
fragment – enzyme
CL-11 Collectin-11
CLU Clusterin (ApoJ,
Sp40,40)
MAP-1 Previously Map44
Properdin MAP-2 Previously Map19,
sMAP
Protein
complexes
C1 C1qr2s2
Activated C1 Activated complex
(containing
activated/cleaved
C1s)
One modification was made to remove 2014 proposed nomenclature for clusterin.
(Bottom) (gray): updated complement nomenclature.
active catalytic site of each C1r and C1s in the activated C1
complex (i.e., four C1-INH molecules are needed to inhibit the
activity of the two activated C1r and two activated C1s molecules
per C1 complex). This interaction also mediates dissociation
of C1r and C1s from the C1q molecule. However, there is
no “inactive” form of C1q. Either after the dissociation of the
activated enzymes C1r and C1s from C1q or if synthesized in
tissues in the absence of C1r and C1s, C1q has many activities
as described in a recent review (11) one of which, the silent
clearance of apoptotic cells and cellular debris, is illustrated
in Figure 1C.
LECTIN PATHWAY
The lectin pathway (LP) is activated by multiple PRMs and
associated enzymes (12). The PRMs show specificity toward a
variety of molecular patterns present on pathogens, but also
on endogenous ligands. It is believed that it is the exposure,
orientation and spatial distribution of the molecular structure
that determines whether binding of the PRMs may lead to
complement activation. The PRMs of the LP recognized so far
comprise two protein families: the ficolins including ficolin-1,
ficolin-2, and ficolin-3, formerly known as M-ficolin, L-ficolin,
and H-ficolin, which are encoded by the FCN1, FCN2, and FCN3
genes, respectively, and were previously assigned recommended
names as shown in Table 1. The second PRM protein family of
the LP is the so-called collectins comprising: mannose-binding
lectin (also named MBL or mannan-binding lectin or protein),
collectin-10 (also named CL-10, collectin liver-1, or CL-L1) and
collectin-11 (also named CL-11 or collectin kidney-1, or CL-
K1), which are encoded by the MBL2, COLEC10, and COLEC11
genes, respectively. A large proportion of CL-10 and CL-11 are
found as heteromeric complexes in the circulation (CL-10/CL-
11 also named CL-LK). We propose that MBL remains as earlier
designated and that collectin-10 and collectin-11 designate the
latter two members of this family, using the abbreviations CL-10
and CL-11, respectively (Table 1). The above proposals relate to
the PRMs of the LP in higher primates, while in lower primates
and in other animal species the number and expression of LP
PRMs might differ, and the nomenclature may not be directly
comparable particularly for the ficolins and for MBL.
The LP PRMs circulate in the blood in complex with
associated serine proteases abbreviated MASP-1,−2, and−3 after
their original discovery of being associated with MBL. The
MASP1 gene encodes the serine proteases MASP-1 and MASP-
3 as well as the non-enzymatically active MAP-1 (also named
Map44), while the MASP2 gene encodes MASP-2 and the non-
enzymatically active MAP-2 (also named Map19 or sMAP).
MASP-1,−2, and−3 are composed of an N-terminal heavy chain
and a C-terminal light chain containing the serine protease
domain, whereas the non-enzymatically active MAPs express
unique exons, but only express part of the heavy chains and
possess no serine protease domains. The different MASPs and
MAPs arise from alternative splicing of the MASP1 and MASP2
genes. When the PRMs-MASPs complexes recognize ligands, LP
complement activation is subsequently initiated upon MASP-2-
mediated cleavage of C4 and C2. MASP-2 was thought mainly
to be activated by autoactivation. However, recently it has been
shown that MASP-1 may activate MASP-2 and cleave C2, but not
C4 and is thus critical in the initiation of the LP. The function
of MASP-3 has long been an enigma, but at least one of its
functions appears to be cleaving pro-FD to mature active FD
enabling activation of the alternative pathway. The MAPs are
thought to be regulators of the activity of the LP, but this has so
far only been convincingly demonstrated for MAP-1 (Map44).
We propose to align the names of the proteins in the lectin
pathway of complement with the common nomenclature in the
gene databases. The 2014 proposed use of the terms MASP-1,
MASP-2, and MASP-3 are reasonable, as are MAP-1 and MAP-2
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used for the non-enzymatically active alternative splice variants
of the MASP1 and MASP2 genes, respectively. However, we also
suggest that the abbreviationsMASP-1, MASP-2, MASP-3, MAP-
1, and MAP-2 in the future will be the names of the proteins
without the need for using the “MBL-associated” as that only
explains a fraction of their associations.
CLUSTERIN
Clusterin is a multifunctional glycoprotein known in the
complement field as binding to C5b-9 complexes sequestering
soluble C5b-9 to prevent host membrane interaction and thus cell
and tissue damage (13). However, it is also involved in clearance
of misfolded proteins including amyloid ß (14), and clusterin
has a risk variant associated with Alzheimer’s disease in humans.
There are now many publications that abbreviate clusterin as
CLU (in line with its gene name, CLU), rather than the Cn
that was recommended in the 2014 report (5), and CLU was
used in the Complement Factsbook 2nd Edition (7) to designate
clusterin. Thus, we recommend that the CLU, not Cn, be used as
the abbreviation for clusterin.
PROPERDIN
Properdin, discovered 1954 by Pillemer et al. (15), is currently
the only known positive regulator of complement activation.
Properdin recognizes and binds to the C3 convertase leading
to a 5–10 fold increase in the stability of this enzyme complex
(16). Aside from increasing the half-life of the C3 convertase,
properdin—after interacting with specific glycosaminoglycans—
can also directly initiate complement activation on some
altered self-surfaces, such as apoptotic cells, by directing
C3b deposition (17). Abbreviating properdin as FP (Factor
Properdin) to bring it in line with FB, FD, FH, and FI,
was briefly considered among the complement community but
was abandoned as the overwhelming majority of publications
used, and uses, the term properdin without any arising
issues. Thus, we recommend that properdin be used as the
sole term.
To conclude, we hope that the updates proposed here
for cleavage fragments, PRMs, activation states and regulatory
proteins of the complement system will enhance communication
and thus understanding of both the basic complement pathways
and consequences of activation or lack thereof, as well as, the
newly discovered nuances of the complement system in the
classroom, in research, in pharma and in the boardroom. It is
hoped that the simplified uniform nomenclature of this intricate
system will facilitate therapeutic development and appropriate
application to the clinic. We propose that the ICS consider
and endorse these changes and submit them to the IUIS
Nomenclature Committee.
AUTHOR CONTRIBUTIONS
AT initiated work. SB, PG, CK, and AT contributed to draft,
revision, and approval of final version.
FUNDING
This contribution was supported by funds from NIH National
Institute of Allergy and Infectious Diseases R15AI117474-01A1
(SB), the Division of Intramural Research, National Heart, Lung,
and Blood Institute, NIH (CK) as well as Danish Research
Foundation of Independent Research [DFF-6110-00489], the
Novo Nordisk Research Foundation and the Sven Andersen
Research Foundation (PG) and NIH National Institute on Aging
R01 AG060148 (AT).
ACKNOWLEDGMENTS
The authors wish to acknowledge previous work from the
International Complement Society (ICS) Complement
Nomenclature Committee, and the ICS and European
Complement Network (ECN) Boards that inspired continued
improvement and refinement of complement nomenclature.
The recommendations provided here are proposals from the
authors to the complement community and were assembled
independently of established committees and boards.
REFERENCES
1. Ricklin D, Lambris JD. Complement in immune and inflammatory
disorders: pathophysiological mechanisms. J Immunol. (2013) 190:3831–8.
doi: 10.4049/jimmunol.1203487
2. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell
Mol Med. (2008) 12:1074–84. doi: 10.1111/j.1582-4934.2008.00350.x
3. Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel
mechanisms and functions of complement. Nat Immunol. (2017) 18:1288–98.
doi: 10.1038/ni.3858
4. Kemper C, Kohl J. Back to the future - non-canonical functions of
complement. Semin Immunol. (2018) 37:1–3. doi: 10.1016/j.smim.2018.
05.002
5. Kemper C, Pangburn MK, Fishelson Z. Complement nomenclature
2014. Mol Immunol. (2014) 61:56–8. doi: 10.1016/j.molimm.2014.
07.004
6. Rapp HJ, Borsos T. Complement and Hemolysis. Science. (1963) 141:738–40.
doi: 10.1126/science.141.3582.738
7. Barnum SR, Schein TN. The Complement Factsbook. London:
Elsevier/Academic Press (2018).
8. Liszewski MK, Atkinson JP. The complement system. In: Paul WE,
editor. Fundamental Immunology. New York, NY: Raven Press Ltd (1993).
p. 917–39.
9. Bornmann L, Mutz R. Growth rates of modern science: a bibliometric
analysis based on the number of publications and cited references.
J Assoc Inform Sci Technol. (2015) 66:2215–22. doi: 10.1002/
asi.23329
10. Ziccardi RJ, Tschopp J. The dissociation properties of native
C1. Biochem Biophys Res Commun. (1982) 107:618–23.
doi: 10.1016/0006-291X(82)91536-4
11. Thielens NM, Tedesco F, Bohlson SS, Gaboriaud C, Tenner AJ. C1q:
a fresh look upon an old molecule. Mol Immunol. (2017) 89:73–83.
doi: 10.1016/j.molimm.2017.05.025
12. Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, et al.
A journey through the lectin pathway of complement-MBL and beyond.
Immunol Rev. (2016) 274:74–97. doi: 10.1111/imr.12468
Frontiers in Immunology | www.frontiersin.org 5 June 2019 | Volume 10 | Article 1308
Bohlson et al. Complement Nomenclature Revisited
13. Tschopp J, Chonn A, Hertig S, French LE. Clusterin, the human
apolipoprotein and complement inhibitor, binds to complement
C7, C8 beta, and the b domain of C9. J Immunol. (1993) 151:2
159–65.
14. Nelson AR, Sagare AP, Zlokovic BV. Role of clusterin in
the brain vascular clearance of amyloid-beta. Proc Natl
Acad Sci USA. (2017) 114:8681–2. doi: 10.1073/pnas.17113
57114
15. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw
AC. The properdin system and immunity. I Demonstration and
isolation of a new serum protein, properdin, and its role in immune
phenomena. Science. (1954) 120:279–85. doi: 10.1126/science.120.31
12.279
16. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization
of the C3b-dependent C3 convertase. J Exp Med. (1975) 142:856–63.
doi: 10.1084/jem.142.4.856
17. Kemper C, Mitchell LM, Zhang L, Hourcade DE. The complement
protein properdin binds apoptotic T cells and promotes complement
activation and phagocytosis. Proc Natl Acad Sci USA. (2008) 105:9023–8.
doi: 10.1073/pnas.0801015105
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Bohlson, Garred, Kemper and Tenner. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 1308
